Goodwin Advises Akero Therapeutics on the Closing of Its $402.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
February 05, 2025
February 05, 2025
BOSTON, Massachusetts, Feb. 5 -- Goodwin, a law firm, issued the following news release:
The Life Sciences team advised Akero Therapeutics on the closing of its previously announced underwritten public offering of (i) 6,427,170 shares of its common stock at a public offering price of $48.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to an additional 1,093,750 shares of common stock, and (ii) in lieu of common stock to certain in . . .
The Life Sciences team advised Akero Therapeutics on the closing of its previously announced underwritten public offering of (i) 6,427,170 shares of its common stock at a public offering price of $48.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to an additional 1,093,750 shares of common stock, and (ii) in lieu of common stock to certain in . . .